Monday, 16 January 2017

Smoking Cessation Market Analysis Report 2023 By Radiant Insights, Inc

Smoking Cessation Pharmaceutical, Commercial & Strategic Developments in the Global Smoking Cessation Market 2013-2023
In April 2013 the US Food & Drug Agency (FDA) announced its plan to relax rules regarding the use and labelling of over-the-counter nicotine replacement therapies.
On April 1st 2013, FDA Commissioner Margaret A. Hamburg M.D. stated, “The agency heard from several public health groups that the labelling for OTC NRT products may stop consumers who are trying to quit smoking from using them. The FDA hopes the recommended changes will allow more people to use these products effectively for smoking cessation and that tobacco dependence will decline in this country.” Will new changes increase take-up of smoking cessation products? This report tells you.
The global smoking cessation market is forecast to reach $4.4bn in 2023, but what will it be this year? Next year? and in 5 years’ time?
New smoking cessation report outlines the key factors affecting the market across the forecast period 2013-2023. The report outlines essential drivers and restraints in all key global geographies.


Nicoderm and Habitrol are the primary NRT products on the market, accounting for over 80% of the global NRT market revenue in 2013. Bupropion and Varenicline are the major products in the prescription drug segment of the smoking cessation market. But what are the 5 key drivers of the global smoking cessation market?
1) Increased health care / health education in many geographies
2) Adoption of smoking cessation products onto health insurance policies
3) Increasing number of smoking cessation products emerging onto the market
4) Emergence of e-cigarettes onto the global market
5) Over 1bn smokers worldwide
This report analysis your market, in key geographic segments; explains in which direction each key market will grow across the next 10 years, and why. Can you afford to ignore this report?
Key challenges for you & your competition
The key challenges that must be faced in the smoking cessation market include; a weak R&D pipeline, off putting side effects affecting key smoking cessation drugs and the challenge of multiple e-cigarette brands encroaching the traditional NRT marketplace.
Only by ordering this in-depth exclusive report will you have full access to the unique findings. This information is not available anywhere else. Find full details of these approved drugs alongside key cancer drugs in their testing phases in this new GMR Data report.
This report also breaks down the market in terms of current smoking cessation drugs and products that occupy the market at present; examining the key prescription and OTC drugs that drive the market. In addition to this crucial information this report offers analysis and opinion on current R&D in the smoking cessation sector alongside in depth analysis of the emerging, global e-cigarette market.
Discover exactly what the industry leaders are doing TODAY -
Within ‘Smoking Cessation - Data, Analysis & Forecasts to 2023’ we analyse the key cessation products and drugs in the market currently and how they will perform across the next decade.
Our study focuses on the individual revenues of the top Smoking Cessation products. With variable patents and the threat of generics, how will these key products fare across the next decade? – ONLY THIS UNIQUE REPORT WILL TELL YOU
We also include analysis of key NRT (Nicotine Replacement Therapies such as NicoDerm CQ; Nicotrol; Habitrol (Nicotinell) and Nicorette. Also analysed are the prescription drugs for smoking cessation, such as: Chantix (by Pfizer): Varenicline and Zyban / Wellbutrin (by GSK): bupropion.
With assessment of the leading players in smoking cessation including: Pfizer; GlaxoSmithKline (GSK); Novartis; Johnson & Johnson (J&J); Perrigo; Sophomore and Extab plus 22nd Century Group, Inc.
PLUS – In-depth country analysis – Discover which countries and regions will drive the smoking cessation drugs market to 2023?
Prescription drugs in the smoking cessation have proved popular and, to some extent, effective. However, side effects and increasingly severe FDA warnings have put some potential customers off. What this means is that there is still space in the market for new pipeline drugs, with fewer side effects and greater efficacy.
But how will these prescription markets develop? This report will tell you - TODAY
Industry information sourced exclusively for this report. This information is not available anywhere else
Utilising primary and secondary research sources, have interviewed leading smoking cessation specialists within big pharma, R&D, wholesalers, distributors, marketers and key organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.
This report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Smoking Cessation products. This report will arm you with all you and your company require to develop, price, launch and market a smoking cessation product.
With over 100+ pages, and over 85+ pages of charts, tables, figures and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.
See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceutical
About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Web: http://www.radiantinsights.com/
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)